Dare Bioscience, Inc. (DARE)
$0.75+0.00%Close
BUYCRISIS · day 4
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $7M
- Beta
- 1.01
- P/E (TTM)
- -0.95
- Short % float
- 9.84%
- Days to cover
- 3.1
- SI change
- +7.3%
- 1W
- -9.64%
- 1M
- +1.35%
- vs SPY 1W
- -9.50%
- vs SPY 1M
- -1.15%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 0
- GROWTH
- 4
- GARP
- 0
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-
REV YoY-
ROE-
EPS YoY-
ROA-49.1%
GROSS-89
OP-813
NET-804
[VALUATION]
P/E TTM-0.95
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B-19.88
P/FCF-
EV/EBITDA-0.62
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO0.99
ND/EBITDA-
BETA1.01
Company news
FAQ
- What is LOPJLB’s current signal on DARE?
- LOPJLB’s latest quantitative signal on Dare Bioscience, Inc. (DARE) is BUY in a CRISIS regime. Signals are updated daily.
- What market regime is DARE in?
- Dare Bioscience, Inc. (DARE) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Dare Bioscience, Inc. (DARE) do?
- Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation…